期刊文献+

小鼠帕金森病模型多巴胺转运体、脑血流灌注与葡萄糖代谢变化 被引量:6

Striatal dopamine transporter, regional cerebral blood flow and glucose utilization in MPTP-induced Parkinson disease mice model
下载PDF
导出
摘要 目的联合观察不同剂量1甲基4苯基1,2,3,6四氢吡啶(MPTP)对小鼠多巴胺神经系统、局部脑血流灌注和葡萄糖代谢的损伤效应。方法8周龄雄性C57BL6小鼠,按体重腹腔注射0~80mgkg的MPTP,10d后用免疫组织化学法测定黑质酪氨酸羟化酶(TH)阳性细胞数,放射自显影法测定尾壳核多巴胺转运体(DAT)相对含量、尾壳核和丘脑局部血流量与葡萄糖代谢水平。结果随MPTP用量增加,DAT损耗和TH阳性细胞数减少程度均加重,两者呈正相关(r=0.998,P<0.05)。其中80mgkg组平均DAT损耗达79.8%(P<0.001),TH阳性细胞数减少达54.1%(P<0.001)。尾壳核和丘脑局部血流量在各组之间差异无显著性(P>0.2)。尾壳核、丘脑葡萄糖代谢在80mgkg组分别下降了3.0%和5.4%(P<0.05)。结论MPTP引起黑质多巴胺神经元和尾壳核DAT丧失存在明显剂量效应关系,尾壳核和丘脑的局部血流灌注变化不明显,葡萄糖代谢在高剂量组有轻微下降。 Objective To explore the variation of regional cerebral blood flow (rCBF), glucose utilization as well as the neurotoxic effect on dopaminergic neurons induced by neurotoxin 1-methy-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Methods Eight-week old male C57BL/6 mice were given a total dose of 0~80 mg/kg MPTP intraperitoneally. Ten days later the mice were sacrificed for tyrosine hydroxylase (TH)-immunopositive cell counting in substantia nigra using SP immunohistochemistry. Vivo autoradiography was employed to measure striatal dopamine transporter (DAT) loss, rCBF and glucose utilization in striatum and thalamus. Results The extents of DAT depletion and TH-immunopositive cell loss were positively correlated (r=0.998, P<0.05) in a dose-dependent manner with a high DTA loss reached 79.8% (P<0.001) and decreasing TH positive cell to 54.1% (P<0.001) noted in 80 mg/kg MPTP-treated group. There were no statistical differences in rCBF in striatum and thalamus among different groups (P>0.2), while glucose utilization was only slightly reduced in caudate/putamen and thalamus by 3.0% and 5.4% in 80 mg/kg MPTP-treated mice (P<0.05). Conclusion Significant dose-dependent relationship was in presence of MPTP induced dopaminergic neurons loss, changes of rCBF in caudate/putamen and thalamus were not significant, while the glucose utilization was slightly decreased in higher dose group.
出处 《中华核医学杂志》 CAS CSCD 北大核心 2005年第3期151-154,共4页 Chinese Journal of Nuclear Medicine
基金 核医学国家重点实验室基金资助项目
  • 相关文献

参考文献16

  • 1Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinsoo's disease. Exp Neurol,2003, 184: S68-S79.
  • 2Jennings DJ, Seibyl J, Oakes D, et al. Clinical determinants of progressive dopamine transporter loss measured by β-CIT and SPECT. Mov Disord,2002, 17: 1104.
  • 3王坚,蒋雨平,项景德,陈正平,管一晖,赵军,苏惠琳,郭丽萍,杨莉芹,邬剑军,丁正同.^(18)F-FP-β-CIT PET脑显像在早期诊断帕金森病中的意义[J].中华核医学杂志,2003,23(4):216-218. 被引量:24
  • 4王维,于小平,毛俊,刘晟,王小宜,彭光春,王润文.偏侧帕金森病猴模型的影像学对比研究[J].中华放射学杂志,2003,37(1):5-10. 被引量:7
  • 5Brownell AL, Canales K, Chen YI, et al. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson' s disease model.Neuro Image, 2003, 20: 1064-1075.
  • 6Schmidt N, Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J Neurol Transm, 2001, 108: 1263-1282.
  • 7Robinson S, Freeman P, Moore C, et al. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function.Exp Neurol, 2003, 180: 73-86.
  • 8Tanji H, Araki T, Nagasawa H, et al. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. Brain Res,1999, 824: 224-231.
  • 9Bezard E, Dovero S, Bioulac B, et al. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol, 1997, 148: 288-292.
  • 10赵军,林祥通,管一晖,王坚,孙伯民,陈正平,左传涛,张政伟.偏侧帕金森病患者葡萄糖代谢与多巴胺转运蛋白PET显像[J].中华核医学杂志,2003,23(4):219-221. 被引量:9

二级参考文献31

  • 1陈生弟,周孝达,徐德隆,朱承谟,张冀先,国毓智,匡琴芳,李彪.偏侧帕金森病猴模型的脑血流灌注SPECT在体显像研究[J].中华核医学杂志,1994,14(4):209-210. 被引量:14
  • 2林岩松,林祥通,张天谊,王博诚.帕金森病模型大鼠脑多巴胺D_2受体放射自显影、病理形态学及行为的联合观察[J].核技术,1996,19(11):641-645. 被引量:5
  • 3王新德.帕金森病及帕金森综合征的诊断标准和鉴别诊断[J].中华神经精神科杂志,1985,18(4):256-256.
  • 4Kempster PA, Gibb WR, Stem GM, et al. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related mootor fluctuations. J Neurol Neurosurg Psychiatry, 1989, 52:72-76.
  • 5Brooks DJ. Monitoring neuroprotection and restorative therapies in Parkinson's disease with PET. J Neural Transm, 2000, 60 Suppl: 125-137.
  • 6Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol, 2003, 53: S110-S118.
  • 7Nurmi E, Raottinen H, Kaasinen V, et al. Progression in Parkinson's disease: a positron emission tomography study with a doparaine transporter ligand ^18F-CFT. Ann Neurol, 2000, 47: 804-808.
  • 8Ribeiro MJ, Vidailhet M, Loc'h C, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol, 2002, 59: 580-586.
  • 9Hu MTM, Taylor-Robinson SD, Chaudhuri KR, et al. Cortical dysfunction in non-demented Parkinson's disease peients: a combined ^31P-MRS and ^18F-FDG-PET study. Brain, 2000, 123: 340-352.
  • 10Eidelberg D, Moeller JR, Ishikawa T, et al. Assessment of disease severity in Parkinsonism with ^18F-fluoradeoxyglucose and PET. J Nucl Med,1995, 36: 378-383.

共引文献52

同被引文献57

引证文献6

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部